BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 35533682)

  • 1. Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.
    Mutlu L; Tymon-Rosario J; Harold J; Menderes G
    Expert Rev Anticancer Ther; 2022 Jun; 22(6):633-645. PubMed ID: 35533682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.
    McNamara B; Chang Y; Mutlu L; Harold J; Santin AD
    Expert Opin Biol Ther; 2023 Mar; 23(3):227-233. PubMed ID: 36800548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature.
    D'Oria O; Bogani G; Cuccu I; D'Auge TG; Di Donato V; Caserta D; Giannini A
    Expert Opin Pharmacother; 2024; 25(1):55-65. PubMed ID: 38159033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
    Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
    Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?
    Vergote I; Ray-Coquard I; Lorusso D; Oaknin A; Cibula D; Van Gorp T
    Expert Opin Investig Drugs; 2023 Mar; 32(3):201-211. PubMed ID: 36803278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
    Coleman RL; Lorusso D; Gennigens C; González-Martín A; Randall L; Cibula D; Lund B; Woelber L; Pignata S; Forget F; Redondo A; Vindeløv SD; Chen M; Harris JR; Smith M; Nicacio LV; Teng MSL; Laenen A; Rangwala R; Manso L; Mirza M; Monk BJ; Vergote I;
    Lancet Oncol; 2021 May; 22(5):609-619. PubMed ID: 33845034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Top advances of the year: Cervical cancer.
    Podwika SE; Duska LR
    Cancer; 2023 Mar; 129(5):657-663. PubMed ID: 36609769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
    Minion LE; Tewari KS
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tisotumab vedotin for the treatment of cervical carcinoma.
    Song X; Li R; Wang H; Song P; Guo W; Chen ZS
    Drugs Today (Barc); 2022 May; 58(5):213-222. PubMed ID: 35535813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent or primary metastatic cervical cancer: current and future treatments.
    Gennigens C; Jerusalem G; Lapaille L; De Cuypere M; Streel S; Kridelka F; Ray-Coquard I
    ESMO Open; 2022 Oct; 7(5):100579. PubMed ID: 36108558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review.
    Ollivier L; Moreau Bachelard C; Renaud E; Dhamelincourt E; Lucia F
    Front Immunol; 2023; 14():1201675. PubMed ID: 37539054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab for the treatment of cervical cancer.
    Bizzarri N; Ghirardi V; Alessandri F; Venturini PL; Valenzano Menada M; Rundle S; Leone Roberti Maggiore U; Ferrero S
    Expert Opin Biol Ther; 2016; 16(3):407-19. PubMed ID: 26796332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tisotumab vedotin in recurrent or metastatic cervical cancer.
    Bogani G; Coleman RL; Vergote I; Raspagliesi F; Lorusso D; Monk BJ
    Curr Probl Cancer; 2023 Jun; 47(3):100952. PubMed ID: 36842202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.
    Krill LS; Tewari KS
    Expert Opin Pharmacother; 2015 Apr; 16(5):675-83. PubMed ID: 25643984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives.
    Giudice E; Mirza MR; Lorusso D
    Curr Oncol Rep; 2023 Nov; 25(11):1307-1326. PubMed ID: 37870697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
    Bose CK
    Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in Cervical Cancer.
    Mauricio D; Zeybek B; Tymon-Rosario J; Harold J; Santin AD
    Curr Oncol Rep; 2021 Apr; 23(6):61. PubMed ID: 33852056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.
    Monk BJ; Enomoto T; Kast WM; McCormack M; Tan DSP; Wu X; González-Martín A
    Cancer Treat Rev; 2022 May; 106():102385. PubMed ID: 35413489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data.
    Agostinelli V; Musacchio L; Camarda F; Salutari V; Carbone MV; Ghizzoni V; Nero C; Ricci C; Perri MT; Giudice E; Lardino S; Berardi R; Scambia G; Lorusso D
    Cancer Manag Res; 2023; 15():1063-1072. PubMed ID: 37790898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
    O'Malley DM; Oaknin A; Monk BJ; Selle F; Rojas C; Gladieff L; Berton D; Leary A; Moore KN; Estevez-Diz MDP; Hardy-Bessard AC; Alexandre J; Opperman CP; de Azevedo CRAS; Randall LM; Feliu WO; Ancukiewicz M; Ray-Coquard I
    Gynecol Oncol; 2021 Nov; 163(2):274-280. PubMed ID: 34452745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.